XUEMEI CAO
Acupuncture at Stockbridge Rd, Scituate, MA
License number
Massachusetts 000650
Category
Acupuncture
Type
Acupuncturist
Address
Address
97 Stockbridge Rd, Scituate, MA 02066
Phone
(781) 424-4542
Personal information
See more information about XUEMEI CAO at radaris.comName
Address
Phone
95 Stockbridge Rd, Scituate, MA 02066
97 Stockbridge Rd, Scituate, MA 02066
Scituate, MA
Professional information
See more information about XUEMEI CAO at trustoria.com
Safe Mutant Viral Vaccines
Safe Mutant Viral Vaccines
US Patent:
7754222, Jul 13, 2010
Filed:
Apr 4, 2008
Appl. No.:
12/098015
Inventors:
Jay Gregory Calvert - Otsego MI, US
Michael K O'Hara - Kalamazoo MI, US
Xuemei Cao - Scituate MA, US
Michael K O'Hara - Kalamazoo MI, US
Xuemei Cao - Scituate MA, US
Assignee:
Pharmacia & Upjohn Company, LLC - Kalamazoo MI
International Classification:
A61K 39/12, A61K 39/295
US Classification:
4242181
Abstract:
The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
Marked Bovine Viral Diarrhea Virus Vaccines
Marked Bovine Viral Diarrhea Virus Vaccines
US Patent:
2008030, Dec 11, 2008
Filed:
Nov 24, 2006
Appl. No.:
11/995779
Inventors:
Chichi Huang - Berwyn PA, US
Michael G. Sheppard - Victoria, AU
Xuemei Cao - Scituate MA, US
Gabriele M. Zybarth - Westport MA, US
Michael G. Sheppard - Victoria, AU
Xuemei Cao - Scituate MA, US
Gabriele M. Zybarth - Westport MA, US
International Classification:
A61K 39/12, C12N 7/00, C12Q 1/70
US Classification:
4242181, 4352351, 435 5
Abstract:
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals.
Marked Bovine Viral Diarrhea Virus Vaccines
Marked Bovine Viral Diarrhea Virus Vaccines
US Patent:
2012002, Jan 26, 2012
Filed:
Jun 22, 2011
Appl. No.:
13/165877
Inventors:
Chichi Huang - Berwyn PA, US
Michael G. Sheppard - Victoria, AU
Xuemei Cao - Scituate MA, US
Gabriele M. Zybarth - Westport MA, US
Michael G. Sheppard - Victoria, AU
Xuemei Cao - Scituate MA, US
Gabriele M. Zybarth - Westport MA, US
Assignee:
PFIZER INC. - New York NY
International Classification:
A61K 39/12, C12Q 1/70, C12N 7/00
US Classification:
4242181, 4352351, 435 5
Abstract:
The present invention is directed to a bovine viral diarrhea virus comprising at least one helicase domain amino acid mutation wherein the mutation in the NS3 domain results in a loss of recognition by a monoclonal antibody raised against wild-type NS3 but wherein viral RNA replication and the generation of infectious virus is retained. The present invention is useful, for example, to produce a marked bovine viral diarrhea virus vaccine or to differentiate between vaccinated and infected or unvaccinated animals.
Safe Mutant Viral Vaccines
Safe Mutant Viral Vaccines
US Patent:
7361357, Apr 22, 2008
Filed:
Jul 16, 2004
Appl. No.:
10/893712
Inventors:
Jay Gregory Calvert - Otsego MI, US
Michael K. O'Hara - Kalamazoo MI, US
Xuemei Cao - Scituate MA, US
Michael K. O'Hara - Kalamazoo MI, US
Xuemei Cao - Scituate MA, US
Assignee:
Pfizer Inc. - New York NY
Pfizer Products Inc. - Groton CT
Pfizer Products Inc. - Groton CT
International Classification:
A61K 39/12
US Classification:
4242181
Abstract:
The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic adds contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.